{ "schemaVersion": "deck-intelligence.v1", "id": "019de076-e431-717d-85d5-60fbb8c86744", "slug": "9614dd2dbfdf83d72e770ebfe5753af3", "title": "Nuvalent | Investor Presentation Deck | 42 slides", "subtitle": "Nuvalent · 2024-02", "author": "Nuvalent", "date": "2024-02-01 00:00:00", "pageCount": 42, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de076-e431-717d-85d5-60fbb8c86744", "slug": "9614dd2dbfdf83d72e770ebfe5753af3", "title": "Nuvalent | Investor Presentation Deck | 42 slides", "rawTitle": "Nuvalent | Investor Presentation Deck | 42 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "authorDisplay": "Nuvalent", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2024-02__nuvalent__investor-pres__9614dd2d.pdf", "sourceUrl": "https://www.slidebook.io/company/nuvalent/presentation/9614dd2dbfdf83d72e770ebfe5753af3/", "sourceDate": "2024-02-12 00:00:00", "presentationDate": "2024-02-01 00:00:00", "ingestedAt": "2026-04-30 22:16:21.397695+00", "status": "ready", "pageCount": 42, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2024-02__nuvalent__investor-pres__9614dd2d", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 42, "pagesIndexed": 42, "pagesWithImages": 42, "pagesWithMetadata": 42, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 216, "chartCount": 20, "metricSlides": 0, "toolMatches": 19, "documentToolMatches": 0, "frameworkMatches": 16, "arcMatches": 1, "beatMatches": 4, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "evidence": "The deck follows a similar structure to the Sequoia Pitch, with sections on problem, solution, market sizing, and traction", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:04.460664+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 9, "name": "Problem", "beatId": "44f9f117-549b-472e-88fc-7cda82a56671", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The deck presents a clear problem statement on slide 9", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 10, "name": "Solution", "beatId": "376f0c82-5c31-4d23-9e34-38fa3ab66e89", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The deck presents a clear solution on slide 10", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 11, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 11, "name": "Market Size", "beatId": "d9688dcd-6a74-4258-a922-fde4e6f9f31c", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "The deck presents market sizing information on slide 11", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 11, "from": 9, "loop": { "name": "02_pattern_hunter", "slug": "02-pattern-hunter", "status": "active", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "canonId": "019dd956-6695-771a-be2e-f1748ef041a4", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "description": "Group multiple pieces of evidence that together point to a pattern or conclusion", "familyLabel": null, "categoryName": "Logical Reasoning", "categorySlug": "logical-reasoning" }, "matchId": "65c3da30-3c59-494a-9036-da2194dedf71", "evidence": "The deck presents a clear pattern of limitations with current therapies and how Nuvalent's solution addresses them", "position": 0, "objective": "What are the limitations of current therapies and how does Nuvalent's solution address them?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:43:04.689841+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 20, "from": 17, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "768b9693-f057-40a9-8283-be0c1cfc71ac", "evidence": "The deck presents data on the cost of inaction for cancer patients and how Nuvalent's solution addresses this", "position": 1, "objective": "What is the cost of inaction for cancer patients and how does Nuvalent's solution address this?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:04.726678+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2d16d5f2-7620-483b-a3f5-3bce6b0487d9", "evidence": "callout/primary: PRECISELY Targeted Therapies for patients with cancer", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:45.596798+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Action Titles", "slug": "action-titles", "status": "active", "bestFor": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "canonId": "019dd956-ac70-700b-a608-ba58e78f5dcc", "version": 1, "bodyDocId": "816dad3c-9983-41c1-a86e-978ebd582841", "description": "The McKinsey-bred discipline of writing every slide title as a complete declarative sentence with a verb and an insight, not a topic label. Each title is a sub-claim that ladders up to the deck's governing thought; read in sequence, the titles reconstruct the executive summary.", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "604ce47b-d1f6-4b40-8de1-07931f28e356", "evidence": "title/action-title: Precisely Targeted Therapies for patients with cancer", "pageRefs": null, "priority": "Core", "whenToUse": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "confidence": 0.7, "extraction": { "at": "2026-07-17 00:43:45.725514+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": "Solves two failure modes at once. (1) The buried claim: action titles place the conclusion on the page before any analysis is read, so a busy reader doesn't reverse-engineer it from the chart. (2) The spineless deck: because each title is a claim, slides have to ladder up to the governing thought; logical gaps become visible as topic-shaped titles in a sequence that no longer reads as a story.", "antipattern": "Topic labels disguised as titles — Volume by quarter, Key findings, Pricing strategy, Margins have been impacted. No verb, or a passive verb with no agent, or a fact (Revenue grew 12%) without the so-what. Also: titles that overreach the chart's evidence, multi-claim X-grew-but-Y-fell welded titles, and mechanical repetition of the same X-drove-Y template across the deck.", "cardinality": null, "narrativePurpose": "Forces the deck to carry its argument in the title bar so a senior reader can extract the recommendation without opening a single slide; converts a binder of topics into a navigable pyramid where every slide is a node defending the apex." }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "8af90262-6fd7-40a5-8738-2efd7ddb26bb", "evidence": "list/bullet: Parallel lead programs for ROS1+ and ALK+ NSCLC in global clinical development.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:45.69383+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "64360425-cede-4063-8f13-b30f214d60a1", "evidence": "list/bullet: Deep Expertise in Chemistry and Structure-based Drug Design.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:45.789526+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "6c2b3747-97b7-4693-9bf7-5c16ca750801", "evidence": "table/data: Comparison of ALK+ and ROS1+ NSCLC treatment landscapes across 1L, 2L, and 3L+ lines of therapy.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:45.97238+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "764faede-02cc-47eb-ab62-2247763b691c", "evidence": "table/data: Comparison matrix of Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib vs NVL-655 across ALK activity, mutant activity, CNS activity, and TRK sparing.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:46.16537+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2e9cef62-0280-4fff-98c0-e39b220e0cd1", "evidence": "table/data: Enrollment table showing NVL-655 Dose Cohorts (BOIN, Expansion, All-Treated, NSCLC Response-Evaluable) across dose levels (15mg to 200mg QD).", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:46.292173+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "5fad3c4b-fdc4-4f8b-bfbe-6b70c0261579", "evidence": "table/data: Patient characteristics and treatment history table for N=93 patients", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:46.355867+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "339702aa-a0e2-4d89-a250-d177a97fa745", "evidence": "table/data: Table showing ORR and Best Response (PR, SD, PD, NE) across patient cohorts including CNS metastases, resistance mutations, and prior TKI history.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:46.419248+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "b69ff297-f862-4a30-b1d9-f4869506b2b7", "evidence": "chart/waterfall: Waterfall plot of tumor response", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:43:54.552123+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4ff8c551-4373-4c83-a9c4-92f76919cf76", "evidence": "list/bullet: EML4-ALK fusion NSCLC with no known ALK resistance mutations; 5 lines of therapy; NVL-655 (50 mg QD); Complete resolution of brain metastases; Treatment continues at 4.2 months", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:43:54.672074+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "93913543-1f8f-4dc3-875e-61475592707d", "evidence": "table/data: Treatment-Related Adverse Events (TRAEs) in ≥ 5% of patients. All Treated Patients (N = 93). Columns: Grade 1, Grade 2, Grade ≥3, Any Grade.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:43:54.752858+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "7e5f7b10-93f2-4a79-8889-fa33847c6028", "evidence": "chart/line: NVL-655 Pharmacokinetics at Steady State (Day 15)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:43:54.833748+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "18b89dae-952a-4272-bfa3-21bd6c4f109f", "evidence": "list/bullet: 2L column: Current SOC Lorlatinib, ~50% single mutations, >60% CNS disease. Opportunity to differentiate with deep, durable responses and TRK-sparing profile.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:43:54.915024+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Call to action", "slug": "call-to-action", "status": "active", "bestFor": null, "canonId": "019dd9e1-4bbb-702a-9ead-82daf188bb7c", "version": 1, "bodyDocId": null, "description": "Explicit prescription of what the audience should do next.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "66e7c45a-40ee-461c-bf5a-0364e84fade5", "evidence": "callout/primary: AT A GLANCE", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:43:55.037857+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Customer journey map", "slug": "customer-journey-map", "status": "active", "bestFor": null, "canonId": "019de52d-1b26-7499-98c8-1091acc836be", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "916d957e-90d9-458b-ab62-79fae54724a9", "evidence": "diagram/timeline: 1L to 2L+ treatment progression", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:43:55.118892+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "a2e10bb5-8aa6-45f6-a454-531b275b9676", "evidence": "chart/waterfall: Waterfall plot of best percentage change in target lesions.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:43:51.500275+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3f1adcf2-c82d-4632-a899-d768a2d4ea01", "evidence": "list/bullet: CNS Activity: Intracranial PR in 3/3 patients with measurable (>10 mm) CNS metastases; ORR of 73% (8/11) in response-evaluable patients with history of CNS metastases; No CNS progression observed in any of t", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:43:51.566074+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 34, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "1261e3d6-b1ce-454d-994b-9b061ef15ada", "evidence": "list/bullet: Clinical activity observed in heavily pretreated patients with ROS1+ NSCLC: Who likely exhausted all available therapies (ORR: 50%); With ROS1 resistance mutations (ORR: 78%); With history of CNS metastasis", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:43:51.694366+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 37, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "cc1d5603-012e-4e5a-b033-ca915e906ad0", "evidence": "The slide organizes four key company facts into a 2x2 grid layout.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:42.77+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "frameworkName": "matrix-2x2" }, { "matchId": "883a3cb4-ed87-4736-ba1e-9b5723fbc1de", "evidence": "The slide distills the company's strategic approach into four distinct pillars.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:05:38.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "frameworkName": "core-message-extraction" }, { "matchId": "7b2211aa-15f0-4eb3-b933-2ee2ad7c8053", "evidence": "Chronological presentation of milestones from 2021-2023", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:05:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "timeline" }, { "matchId": "7624976f-ca9b-4941-84a5-1b0d3b3c336e", "evidence": "The slide uses a chronological progression from 2024 to 2026 to illustrate strategic goals.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:05:38.43+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "timeline" }, { "matchId": "26bcec64-6780-46c3-90bf-940c827aaf8d", "evidence": "The slide uses a horizontal bar chart to represent project timelines and phases.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:38.574+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "gantt-chart" }, { "matchId": "b7452c1a-27c2-45ef-b9da-c8b367340d7b", "evidence": "Side-by-side comparison of two clinical landscapes", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:41.423+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "comparison_frame" }, { "matchId": "2f510f60-5860-4f5f-9690-0a6e46d30031", "evidence": "Uses a clinical case study (Osimertinib) to validate the proposed strategy.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:39.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "evidence-matrix" }, { "matchId": "a7dfb54b-6c4a-4bc5-9464-10eeb14d23e3", "evidence": "The slide maps the clinical progression of patients through treatment lines (1L, 2L, 3L+).", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:40.008+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "customer-journey-map" }, { "matchId": "7bc906df-1b10-4e84-8922-073ff1ff0d0b", "evidence": "Matrix comparing drug generations against clinical outcomes", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:39.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "frameworkName": "comparison_table" }, { "matchId": "053c9790-e0bc-45ea-b6a8-bf07a4c806dd", "evidence": "Standard oncology clinical trial visualization", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:05:42.963+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "waterfall-plot" }, { "matchId": "8d1e4a8c-f1ea-44b8-8b19-15615718998d", "evidence": "The slide presents clinical evidence (PK data and patient outcomes) to support a strategic decision (RP2D selection).", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:05:40.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "frameworkName": "evidence-matrix" }, { "matchId": "9a012132-b9b4-4894-9014-1878d2e492ca", "evidence": "Segmentation by treatment line (1L, 2L, 3L+)", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:05:41.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "frameworkName": "market-segmentation-pyramid" }, { "matchId": "c71ff29c-0dc6-4188-82dd-f79108e133f1", "evidence": "The slide explicitly maps the patient treatment journey from 1L to 2L+.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:41.397+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "frameworkName": "customer-journey-map" }, { "matchId": "da95ea37-08a5-428f-b10f-f3cb92635426", "evidence": "Comparison table of therapeutic features across multiple competitors.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:41.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "frameworkName": "comparison_frame" }, { "matchId": "df8928dd-5424-486f-a7ad-b52e85923181", "evidence": "Multi-cohort study structure with registrational intent", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:05:48.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 38, "frameworkName": "Clinical Trial Design" }, { "matchId": "f567bd89-5378-4bd2-a6ad-cceedc25eac7", "evidence": "Chronological progression of goals from 2024 to 2026.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:05:43.236+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 41, "frameworkName": "timeline" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/2qSr9sSQXIl1EMz6yWfRYIa5IkEDzjWyUjKsLxF2F68/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85NjE0ZGQyZGJmZGY4M2Q3MmU3NzBlYmZlNTc1M2FmMy9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 31, "componentCount": 5, "textChars": 128, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:37.205+00", "seconds": 2.434, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/1", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-1", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.2, "x": 0.75, "y": 0.85 }, "kind": "callout", "text": "PRECISELY Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:37.205+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b309da8e-07f0-40d4-b253-d464bf01a6ed", "parentComponentId": null }, { "bbox": { "h": 1, "w": 0.5, "x": 0.5, "y": 0 }, "kind": "image", "text": "Molecular structure visualization", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:37.205+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e2be20cf-c5e7-45e6-9f25-d2f19e51a089", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.08, "y": 0.175 }, "kind": "image", "text": "Nuvalent", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:37.205+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "297a32fe-3c92-456e-96df-b17c00b1d029", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.08, "y": 0.64 }, "kind": "paragraph", "text": "February 12, 2024", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:37.205+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b9bdc1ec-184d-4a87-811c-ae56af4dc374", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.4, "x": 0.08, "y": 0.5 }, "kind": "title", "text": "Nuvalent Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:37.205+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb139004-e2ac-4fc2-a7cf-4b74abaf1add", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2d16d5f2-7620-483b-a3f5-3bce6b0487d9", "evidence": "callout/primary: PRECISELY Targeted Therapies for patients with cancer", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:45.596798+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/pMYfIB03SW7MjNQvo6TgDTfobIPxYG69GTBoTrb4qSI/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85NjE0ZGQyZGJmZGY4M2Q3MmU3NzBlYmZlNTc1M2FmMy9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/p3xs_rZs7t3HanfZIcjvb8WOb68fOFGtHRJmpn_c8fI/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85NjE0ZGQyZGJmZGY4M2Q3MmU3NzBlYmZlNTc1M2FmMy9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/s2YpKJ57QYpwNqZDdEUmKT5xI1VatDlO-TluUErXpU8/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85NjE0ZGQyZGJmZGY4M2Q3MmU3NzBlYmZlNTc1M2FmMy9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "dense", "densityScore": 53, "componentCount": 5, "textChars": 531, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:39.535+00", "seconds": 4.263, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/2", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-2", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.285, "w": 0.886, "x": 0.057, "y": 0.208 }, "kind": "disclaimer", "text": "This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995... You should not place undue reliance on these statements or the scientific data presented.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "87853117-2dd9-4754-8007-028085015436", "parentComponentId": null }, { "bbox": { "h": 0.385, "w": 0.886, "x": 0.057, "y": 0.515 }, "kind": "disclaimer", "text": "Any forward-looking statements in this presentation are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c6f841d0-327c-40b5-b271-6b91cb142795", "parentComponentId": null }, { "bbox": { "h": 0.038, "w": 0.107, "x": 0.836, "y": 0.925 }, "kind": "image", "text": "Nuvalent", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "84ae6ebc-59f8-4935-9f48-1290999ba796", "parentComponentId": null }, { "bbox": { "h": 0.022, "w": 0.008, "x": 0.055, "y": 0.944 }, "kind": "other", "text": "2", "attrs": null, "canon": { "kind": { "name": "Other", "slug": "other", "status": "active", "canonId": "019de52c-fa90-743c-8bf6-20d1fbe82b6d", "version": 1, "description": "Fallback when no canonical kind applies." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3379ae27-075a-4f2f-a162-7bb448c4bbe0", "parentComponentId": null }, { "bbox": { "h": 0.028, "w": 0.685, "x": 0.057, "y": 0.138 }, "kind": "title", "text": "CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.535+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3ab7d23d-48ee-401d-b0e6-3770551da079", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "title": "The slide uses a 2x2 grid layout to summarize key company metrics.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 70, "componentCount": 8, "textChars": 377, "nDataPoints": 2, "notes": "The slide uses a 2x2 grid layout to summarize key company metrics.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:42.77+00", "seconds": 7.465, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/3", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-3", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.45, "x": 0.5, "y": 0.15 }, "kind": "framework", "text": null, "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.77+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "135efe4e-026b-4485-9b10-52a32af9dac7", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.4, "x": 0.06, "y": 0.45 }, "kind": "list", "text": "Parallel lead programs for ROS1+ and ALK+ NSCLC in global clinical development. Proven discovery capabilities: Third program for HER2+ NSCLC in IND enabling studies & active research pipeline", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.77+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "21e5e965-9eaa-429c-9fe7-757778e4fe2e", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.15, "x": 0.55, "y": 0.2 }, "kind": "metric", "text": "Growing team (90+ FTEs)", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.77+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "77c9fe18-4df2-49b0-b056-d692d67446b4", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.1, "x": 0.8, "y": 0.74 }, "kind": "paragraph", "text": "Nasdaq listed", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.77+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2249c502-9c3c-4769-af18-5f72faf71fe5", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.15, "x": 0.78, "y": 0.34 }, "kind": "paragraph", "text": "Hybrid operations with offices in Cambridge, MA", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.77+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "61b71e70-f463-447a-8461-d397313f26b5", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.15, "x": 0.55, "y": 0.74 }, "kind": "paragraph", "text": "Cash runway expected into 2027", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.77+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ed2fe3bd-127d-42a9-85a8-6f968a706a74", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.38, "x": 0.06, "y": 0.24 }, "kind": "title", "text": "Precisely Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.77+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ba898089-9dda-46f4-b9c7-675b8b190447", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.22, "y": 0.08 }, "kind": "title", "text": "Nuvalent AT-A-GLANCE", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.77+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d7721bdb-3ab5-471c-b14d-f91e382e8c50", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Action Titles", "slug": "action-titles", "status": "active", "bestFor": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "canonId": "019dd956-ac70-700b-a608-ba58e78f5dcc", "version": 1, "bodyDocId": "816dad3c-9983-41c1-a86e-978ebd582841", "description": "The McKinsey-bred discipline of writing every slide title as a complete declarative sentence with a verb and an insight, not a topic label. Each title is a sub-claim that ladders up to the deck's governing thought; read in sequence, the titles reconstruct the executive summary.", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "604ce47b-d1f6-4b40-8de1-07931f28e356", "evidence": "title/action-title: Precisely Targeted Therapies for patients with cancer", "pageRefs": null, "priority": "Core", "whenToUse": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "confidence": 0.7, "extraction": { "at": "2026-07-17 00:43:45.725514+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": "Solves two failure modes at once. (1) The buried claim: action titles place the conclusion on the page before any analysis is read, so a busy reader doesn't reverse-engineer it from the chart. (2) The spineless deck: because each title is a claim, slides have to ladder up to the governing thought; logical gaps become visible as topic-shaped titles in a sequence that no longer reads as a story.", "antipattern": "Topic labels disguised as titles — Volume by quarter, Key findings, Pricing strategy, Margins have been impacted. No verb, or a passive verb with no agent, or a fact (Revenue grew 12%) without the so-what. Also: titles that overreach the chart's evidence, multi-claim X-grew-but-Y-fell welded titles, and mechanical repetition of the same X-drove-Y template across the deck.", "cardinality": null, "narrativePurpose": "Forces the deck to carry its argument in the title bar so a senior reader can extract the recommendation without opening a single slide; converts a binder of topics into a navigable pyramid where every slide is a node defending the apex." }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "8af90262-6fd7-40a5-8738-2efd7ddb26bb", "evidence": "list/bullet: Parallel lead programs for ROS1+ and ALK+ NSCLC in global clinical development.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:45.69383+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "cc1d5603-012e-4e5a-b033-ca915e906ad0", "evidence": "The slide organizes four key company facts into a 2x2 grid layout.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:42.77+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "frameworkName": "matrix-2x2" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "resolution", "title": "The slide uses a 'The Nuvalent Approach' framing to outline their core methodology.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 8, "textChars": 361, "nDataPoints": 0, "notes": "The slide uses a 'The Nuvalent Approach' framing to outline their core methodology.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:38.392+00", "seconds": 3.061, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/4", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-4", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.06, "x": 0.52, "y": 0.1 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c2bb96c2-418e-4d4e-8f20-61d063a7598b", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.52, "y": 0.1 }, "kind": "list", "text": "Deep Expertise in Chemistry and Structure-based Drug Design. Aim to \"thread the needle\" between kinase resistance and selectivity", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0ab079ec-92da-4ebb-9448-32a5139bce34", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.4, "x": 0.52, "y": 0.51 }, "kind": "list", "text": "Aim to Compete in 1st Line with Best-in-Class Profiles", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "689186d3-a086-4d74-9e43-1fc0636e273a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.52, "y": 0.69 }, "kind": "list", "text": "GOAL: Maximize Patient Impact", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "84d1bcea-17ab-45f5-a37d-d09510e6f04c", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.4, "x": 0.52, "y": 0.32 }, "kind": "list", "text": "Design of Target Product Profiles in Collaboration with Physician-Scientists", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8fc1c172-4da4-41aa-be96-e7e752c04fad", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.11, "y": 0.57 }, "kind": "paragraph", "text": "THE NUVALENT APPROACH", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "93961310-e628-4c97-b40b-1f16a33a920f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.07, "y": 0.3 }, "kind": "title", "text": "PRECISELY", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6e24d44c-73eb-4f6f-95de-53e5a727d4ed", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.45, "x": 0.07, "y": 0.38 }, "kind": "title", "text": "Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "540ea67d-3ac1-4c4b-ad27-ba08248cb4db", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "64360425-cede-4063-8f13-b30f214d60a1", "evidence": "list/bullet: Deep Expertise in Chemistry and Structure-based Drug Design.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:45.789526+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "883a3cb4-ed87-4736-ba1e-9b5723fbc1de", "evidence": "The slide distills the company's strategic approach into four distinct pillars.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:05:38.392+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "frameworkName": "core-message-extraction" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 5, "type": "evidence", "title": "The slide uses a timeline-based structure to demonstrate operational momentum.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 80, "componentCount": 7, "textChars": 1015, "nDataPoints": 1, "notes": "The slide uses a timeline-based structure to demonstrate operational momentum.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:43.153+00", "seconds": 7.678, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/5", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-5", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.94, "x": 0.03, "y": 0.205 }, "kind": "callout", "text": "Resource-efficient execution and value creation across an expanding portfolio of wholly-owned programs", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5542fd18-2252-469c-a108-350e1b921f73", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.36, "y": 0.36 }, "kind": "list", "text": "2022 FIRST CLINICAL PROOF-OF-CONCEPT: Initiated two global Phase 1/2 studies, Demonstrated clinical proof-of-concept for ROS1 program, Disclosed third novel program", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0b366639-54f7-400b-b617-a61ed049f55f", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.66, "y": 0.36 }, "kind": "list", "text": "2023 SECOND PROOF-OF-CONCEPT & FIRST PIVOTAL STUDY: Demonstrated clinical proof-of-concept for ALK program, Initiated ARROS-1 Phase 2, Advanced HER2 program", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c012d253-fbb3-49fc-8637-0843c784ddaf", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.06, "y": 0.36 }, "kind": "list", "text": "2021 EMERGENCE FROM STEALTH: Disclosed parallel lead programs, Presented preclinical profiles, Nasdaq listed: NUVL", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fbfbd3eb-b10c-4848-977c-f90b5375dfad", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.7, "x": 0.15, "y": 0.79 }, "kind": "paragraph", "text": "Ended 2023 with approximately $719.9M* in cash, cash equivalents and marketable securities (unaudited), with potential to deliver multiple transformative catalysts within cash runway window into 2027", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ab154e66-cb49-41a0-8d81-837227f69c50", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.9, "x": 0.05, "y": 0.885 }, "kind": "source-note", "text": "* Preliminary, unaudited estimate only as of the date of this presentation; subject to change following completion of year-end closing procedures; does not present all information necessary for an understanding of financial position as of December 31, 2023.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "41b651e6-5a27-4fdb-8639-37f044fe8e14", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.36, "x": 0.32, "y": 0.1 }, "kind": "title", "text": "Track Record of Success", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9636500b-c6be-48e9-bc27-ca5c9c54e478", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "7b2211aa-15f0-4eb3-b933-2ee2ad7c8053", "evidence": "Chronological presentation of milestones from 2021-2023", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:05:43.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 6, "type": "resolution", "title": "The slide uses a timeline to show the progression from global strategy execution to product approval, complemented by a list of 2024 milestones.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 48, "componentCount": 5, "textChars": 408, "nDataPoints": 0, "notes": "The slide uses a timeline to show the progression from global strategy execution to product approval, complemented by a list of 2024 milestones.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:38.43+00", "seconds": 2.656, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/6", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-6", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.4, "x": 0.15, "y": 0.45 }, "kind": "diagram", "text": "2024: Execute on global registrational strategies; 2025: First pivotal data; 2026: First approved product", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.43+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af54b56a-0c59-4952-aad7-85ae337f361e", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.15, "x": 0.7, "y": 0.85 }, "kind": "legend", "text": "KEY | Achieved. Planned.", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.43+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f3c23b3a-c3a7-4781-adf5-6c024b4d3a8c", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.25, "x": 0.7, "y": 0.2 }, "kind": "list", "text": "Anticipated 2024 Milestones: Progress ARROS-1 Phase 2; Initiate ALKOVE-1 Phase 2; Launch 1L ALK strategy; Interim Ph 1/2 data; Initiate Phase 1 trial for HER2", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.43+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4fa9887d-3c4a-4b68-8556-78ea04cb58c9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.2, "y": 0.75 }, "kind": "paragraph", "text": "MISSION: Bringing new, potential best-in-class medicines to patients with cancer", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.43+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff58d78d-e94e-49bd-8f77-e004192abe9f", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "OnTarget 2026: The Path to Patient Impact", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.43+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "28200577-9f0f-4180-a090-4a1256658a92", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "7624976f-ca9b-4941-84a5-1b0d3b3c336e", "evidence": "The slide uses a chronological progression from 2024 to 2026 to illustrate strategic goals.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:05:38.43+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 7, "type": "setup", "title": "The slide uses a split layout with a left-hand sidebar for advisors/board and a right-hand grid for the leadership team.", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 48, "componentCount": 6, "textChars": 197, "nDataPoints": 1, "notes": "The slide uses a split layout with a left-hand sidebar for advisors/board and a right-hand grid for the leadership team.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:38.859+00", "seconds": 3.065, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/7", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-7", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.55, "x": 0.4, "y": 0.1 }, "kind": "image", "text": "Leadership team photos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "064a3654-0668-47ad-8a0f-966cfb74e6a2", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.3, "x": 0.05, "y": 0.28 }, "kind": "list", "text": "BOARD OF DIRECTORS and SCIENTIFIC ADVISORS lists", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "15b720af-2458-4645-9c8a-3150f7a6ca24", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.55, "x": 0.4, "y": 0.82 }, "kind": "metric", "text": "12 Prior FDA Approvals", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e5907369-e6d3-4b35-ab00-7607b8fd255b", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.3, "x": 0.05, "y": 0.18 }, "kind": "title", "text": "Significant experience in drug discovery, development and company building", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a4f890fd-0919-44ba-9977-a10ebb4ad914", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.6, "y": 0.05 }, "kind": "title", "text": "LEADERSHIP TEAM", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0386724b-b82c-4ffa-a4ca-85654cc8b8c7", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Meet the #NuCrew", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "69e6a920-ae31-4cc6-aaeb-0cf4f1fcaf68", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 8, "type": "resolution", "title": "The slide uses a standard pharmaceutical pipeline visualization format.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 27, "componentCount": 4, "textChars": 191, "nDataPoints": 0, "notes": "The slide uses a standard pharmaceutical pipeline visualization format.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:38.574+00", "seconds": 2.746, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/8", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-8", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.9, "x": 0.05, "y": 0.32 }, "kind": "chart", "text": "Pipeline development chart", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.574+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3b0c6257-7c3d-4bc7-a688-ea8dd4b63efb", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.7, "y": 0.9 }, "kind": "source-note", "text": "*KEY | ✓ Milestone achieved. • Planned Milestone.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.574+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d30a2984-b3c6-49f8-b7b3-2ab3ebdd7464", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.18 }, "kind": "title", "text": "Advancing a portfolio of potentially best-in-class products, with complementary initial indications in NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.574+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "549dd6c1-a7cb-4b22-b252-d3bc4b729870", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.13, "x": 0.23, "y": 0.08 }, "kind": "title", "text": "PIPELINE", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:38.574+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8731e20d-1705-4258-ae58-bc8e41afbb6a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "26bcec64-6780-46c3-90bf-940c827aaf8d", "evidence": "The slide uses a horizontal bar chart to represent project timelines and phases.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:38.574+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 9, "type": "tension", "title": "The slide highlights the lack of clear standard of care in later lines of therapy, framing the problem for a potential new therapeutic intervention.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 4, "textChars": 455, "nDataPoints": 10, "notes": "The slide highlights the lack of clear standard of care in later lines of therapy, framing the problem for a potential new therapeutic intervention.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:41.423+00", "seconds": 5.588, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/9", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-9", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.8, "x": 0.05, "y": 0.85 }, "kind": "source-note", "text": "* Repotrectinib was approved November 2023; ** Not FDA approved, but in NCCN guidelines. 1L, 1st line; 2L, 2nd line; 3L, 3rd line; CNS, central nervous system. Sources (ALK): ... Sources (ROS1): ...", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.423+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2ad37a29-d96e-43cf-ab4d-10faa440e93c", "parentComponentId": null }, { "bbox": { "h": 0.48, "w": 0.82, "x": 0.09, "y": 0.315 }, "kind": "table", "text": "Comparison of ALK+ and ROS1+ NSCLC treatment landscapes across 1L, 2L, and 3L+ lines of therapy.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.423+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "92c91c3d-1a86-4a2d-9073-62344924c6a9", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.9, "x": 0.05, "y": 0.18 }, "kind": "title", "text": "Emerging resistance mutations, increasing CNS involvement, and treatment-related adverse events limit utility of approved therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.423+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d1947ef-74af-4362-b45c-d49e45bfa4d7", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "ALK+ and ROS1+ NSCLC Landscape", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.423+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ae083123-0760-4d10-a8b9-7112df80283e", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "6c2b3747-97b7-4693-9bf7-5c16ca750801", "evidence": "table/data: Comparison of ALK+ and ROS1+ NSCLC treatment landscapes across 1L, 2L, and 3L+ lines of therapy.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:45.97238+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "b7452c1a-27c2-45ef-b9da-c8b367340d7b", "evidence": "Side-by-side comparison of two clinical landscapes", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:41.423+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "comparison_frame" } ], "arcBeats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Problem", "beatId": "44f9f117-549b-472e-88fc-7cda82a56671", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The deck presents a clear problem statement on slide 9", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 11, "from": 9, "loop": { "name": "02_pattern_hunter", "slug": "02-pattern-hunter", "status": "active", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "canonId": "019dd956-6695-771a-be2e-f1748ef041a4", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "description": "Group multiple pieces of evidence that together point to a pattern or conclusion", "familyLabel": null }, "matchId": "65c3da30-3c59-494a-9036-da2194dedf71", "evidence": "The deck presents a clear pattern of limitations with current therapies and how Nuvalent's solution addresses them", "position": 0, "objective": "What are the limitations of current therapies and how does Nuvalent's solution address them?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:43:04.689841+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "resolution", "title": "The slide uses a 'Case Study' framework to validate the strategy by comparing it to the established success of Osimertinib in EGFR+ NSCLC.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 80, "componentCount": 7, "textChars": 741, "nDataPoints": 8, "notes": "The slide uses a 'Case Study' framework to validate the strategy by comparing it to the established success of Osimertinib in EGFR+ NSCLC.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:39.293+00", "seconds": 3.317, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/10", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-10", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.35, "x": 0.62, "y": 0.54 }, "kind": "chart", "text": "Significant 1L mPFS improvement & Movement up the treatment paradigm", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d2e13d3-8a7b-4122-bf17-9bcfb9fc518e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.7, "x": 0.15, "y": 0.2 }, "kind": "diagram", "text": "Selective inhibition of the oncogenic driver + Overcoming treatment-emergent resistance mutations + Treating & preventing brain metastases + Avoiding treatment-limiting adverse events", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4cae80be-cf53-46d1-8ecb-7b26c783748f", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.4, "x": 0.05, "y": 0.54 }, "kind": "framework", "text": "CASE STUDY: Osimertinib for EGFR+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0ecdfb53-1951-4c5c-ad5a-3c0aed48d517", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.84, "x": 0.08, "y": 0.46 }, "kind": "paragraph", "text": "Comparable resistance mutation rates after 1L TKI: ~50% ALK single mutation & ~40% ROS1 G2032R vs. ~50% EGFR T790M", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "04756a78-1bfc-4b6c-91c9-d6ed2e7d9558", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.87 }, "kind": "source-note", "text": "Sources: [1] Dagogo-Jack I. et al., Clin Cancer Res 2019; [2] Gainor J. et al. Cancer Discov. 2016; [4] Gainor J.F. et al. JCO Precision Oncol. 2017; [4] Ohashi K. et al., JCO 2013; [5] Osimertinib FDA package insert.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1a2960ca-46cd-4444-8762-e861197c5dd8", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.6, "x": 0.2, "y": 0.15 }, "kind": "title", "text": "Potential best-in-class ALK & ROS1 TKIs to overcome the combined medical needs of:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "78e6ffde-e23b-48d9-9d87-bfd188d7e739", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.52, "x": 0.24, "y": 0.06 }, "kind": "title", "text": "Nuvalent ALK+ and ROS1+ NSCLC Strategy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d88805c7-bb12-4aaa-9338-3c9c8303bae7", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "2f510f60-5860-4f5f-9690-0a6e46d30031", "evidence": "Uses a clinical case study (Osimertinib) to validate the proposed strategy.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:39.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "evidence-matrix" } ], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Solution", "beatId": "376f0c82-5c31-4d23-9e34-38fa3ab66e89", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The deck presents a clear solution on slide 10", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 11, "from": 9, "loop": { "name": "02_pattern_hunter", "slug": "02-pattern-hunter", "status": "active", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "canonId": "019dd956-6695-771a-be2e-f1748ef041a4", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "description": "Group multiple pieces of evidence that together point to a pattern or conclusion", "familyLabel": null }, "matchId": "65c3da30-3c59-494a-9036-da2194dedf71", "evidence": "The deck presents a clear pattern of limitations with current therapies and how Nuvalent's solution addresses them", "position": 0, "objective": "What are the limitations of current therapies and how does Nuvalent's solution address them?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:43:04.689841+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "resolution", "title": "The slide uses a bar chart to segment the $3.1B market into specific drugs and categories.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 5, "textChars": 637, "nDataPoints": 4, "notes": "The slide uses a bar chart to segment the $3.1B market into specific drugs and categories.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:39.483+00", "seconds": 3.298, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/11", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-11", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.35, "x": 0.05, "y": 0.25 }, "kind": "callout", "text": "Meaningful Commercial Markets with ~$3.1B Combined WW Sales in 2023", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.483+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "714b0ee0-8a0b-448b-af00-25c8955ff6c5", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.5, "x": 0.46, "y": 0.12 }, "kind": "chart", "text": "2023 GLOBAL SALES FOR ALK & ROS1 TKIs", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.483+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3ebb291a-6acb-46bb-95c5-246dbe64e7a2", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.35, "x": 0.05, "y": 0.38 }, "kind": "list", "text": "Potential best-in-class profiles designed with the goal to supplant the current 1L standard of care; Potential near-term registrational opportunity for TKI-pretreated patients; Potential to grow the market through deeper, more durable responses", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.483+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "568dbdad-4f1d-4f9b-b8cb-3f820f5dcecb", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.48, "x": 0.47, "y": 0.75 }, "kind": "source-note", "text": "1L, 1st line; 2L, 2nd line; 3L, 3rd line; B, billion; M, million; NCCN, National Comprehensive Cancer Network; NSCLC, non-small cell lung cancer; PFS, progression-free survival; TKI, tyrosine kinase inhibitor. Sources: 2023 Year-End Earnings Reports...", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.483+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b8439a50-9848-4d3c-bdf3-dbc4d098fa81", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.35, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "ALK+ & ROS1+ NSCLC Market Opportunity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.483+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eebb4029-88ab-41af-a4f3-4636d748f1ab", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 11, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 11, "name": "Market Size", "beatId": "d9688dcd-6a74-4258-a922-fde4e6f9f31c", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "The deck presents market sizing information on slide 11", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 11, "from": 9, "loop": { "name": "02_pattern_hunter", "slug": "02-pattern-hunter", "status": "active", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "canonId": "019dd956-6695-771a-be2e-f1748ef041a4", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "description": "Group multiple pieces of evidence that together point to a pattern or conclusion", "familyLabel": null }, "matchId": "65c3da30-3c59-494a-9036-da2194dedf71", "evidence": "The deck presents a clear pattern of limitations with current therapies and how Nuvalent's solution addresses them", "position": 0, "objective": "What are the limitations of current therapies and how does Nuvalent's solution address them?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:43:04.689841+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "resolution", "title": "The slide uses a sidebar 'AT A GLANCE' to summarize key product attributes.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 32, "componentCount": 3, "textChars": 430, "nDataPoints": 0, "notes": "The slide uses a sidebar 'AT A GLANCE' to summarize key product attributes.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:41.521+00", "seconds": 4.807, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/12", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-12", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.875, "w": 0.287, "x": 0.713, "y": 0 }, "kind": "callout", "text": "AT A GLANCE\n\nMechanism of Action:\nALK-selective tyrosine kinase inhibitor\n\nStage of Development:\nGlobal Phase 2 with registrational intent\n\nInitial Development Indication:\nALK-positive NSCLC\n\nFDA Designations:\nOrphan Drug Designation", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.521+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5c332d9a-8d90-4724-89c9-b0b653d999a4", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.65, "x": 0.08, "y": 0.65 }, "kind": "paragraph", "text": "A brain-penetrant, selective inhibitor of ALK and ALK resistance mutations with the potential to minimize TRK-related CNS adverse events while providing CNS antitumor activity", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.521+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "763d1ddc-0cb6-4af6-ac59-d35e8ae8d1fc", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.39, "x": 0.08, "y": 0.46 }, "kind": "title", "text": "NVL-655 for ALK+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.521+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f0a4ba5c-7c7e-48d5-ba22-986cf0819b2c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 13, "type": "setup", "title": "The slide uses a timeline-based framework to map clinical stages (1L, 2L, 3L+) against standard therapies and unmet needs.", "function": "present_framework", "rawType": "customer_journey", "block": null, "metadata": { "slideType": "customer_journey", "slideTypeCanon": { "name": "Customer journey", "slug": "customer_journey", "status": "active", "canonId": "019de52d-0966-70ce-afe3-bc7c98ffc8c9", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 5, "textChars": 696, "nDataPoints": 10, "notes": "The slide uses a timeline-based framework to map clinical stages (1L, 2L, 3L+) against standard therapies and unmet needs.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:40.008+00", "seconds": 3.243, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/13", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-13", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.65, "x": 0.06, "y": 0.2 }, "kind": "diagram", "text": "1L, 2L, 3L+ treatment stages", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.008+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f0391fbe-0377-4617-9088-b55b25e7304d", "parentComponentId": null }, { "bbox": { "h": 0.95, "w": 0.25, "x": 0.75, "y": 0.05 }, "kind": "image", "text": "Illustrative patient image", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.008+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8684104f-fe80-4238-8a42-236afac7dcd9", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.65, "x": 0.06, "y": 0.85 }, "kind": "source-note", "text": "Sources: [1] Kwak E. et al., NEJM 2010. [2] Chia P.L. et al., Clin Epidemiol. 2014. [3] 2023 Year-End Earnings Reports, Roche and Pfizer. [4] NCCN Guidelines for NSCLC (version 1.2024). [5] Basit S. et al., Eur. J. Med. Chem. 2017. [6] Dagogo-Jack I. et al., Clin Cancer Res 2019. [7] Gainor J. et al. Cancer Discov. 2016. [8] Gainor J et al. JCO Precis Oncol. 2017. [9] Shaw A. et al., Lancet Onc 2017. [10] FDA Package Inserts. [11] Cocco E et al., Nat Rev Clin Oncol. 2018. [12] Shaw A. et al., NEJM 2020. [13] Shiba-Ishii et al., Nature Cancer 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.008+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "966a97c4-301b-4c07-aadd-87df9efa6b52", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.7, "x": 0.06, "y": 0.3 }, "kind": "table", "text": "Standard of care and key limitations for 1L, 2L, and 3L+ stages", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.008+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "764d37e9-e6fb-40a7-9998-7bf568f664dd", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.06, "y": 0.08 }, "kind": "title", "text": "ALK+ NSCLC Patient Journey", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.008+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7bf60ae8-9b51-40ef-bd87-4989fc142c38", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "a7dfb54b-6c4a-4bc5-9464-10eeb14d23e3", "evidence": "The slide maps the clinical progression of patients through treatment lines (1L, 2L, 3L+).", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:40.008+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "customer-journey-map" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 14, "type": "setup", "title": "The slide uses a matrix-like structure to compare drug generations against clinical outcomes.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 429, "nDataPoints": 0, "notes": "The slide uses a matrix-like structure to compare drug generations against clinical outcomes.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:39.871+00", "seconds": 3.05, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/14", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-14", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.7, "x": 0.05, "y": 0.89 }, "kind": "disclaimer", "text": "Source: Lin J.J. et al., AACR-NCI-EORTC 2023. Head-to-head clinical studies comparing NVL-655 with currently approved or investigational therapies have not been conducted.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a307b8a4-1691-47c0-8a3a-f26a5cc7c488", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.15, "y": 0.83 }, "kind": "legend", "text": "Observed in clinical investigation", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8544b94e-1047-42bb-b631-79d89fec201a", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "table", "text": "Comparison matrix of Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib vs NVL-655 across ALK activity, mutant activity, CNS activity, and TRK sparing.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "acd56ce2-06c5-48e2-94fb-a419d3b306ff", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "NVL-655: A Rationally Designed ALK-selective, TRK-sparing Inhibitor", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a5cbc097-76f2-4434-bef6-95cd4ce27bff", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "764faede-02cc-47eb-ab62-2247763b691c", "evidence": "table/data: Comparison matrix of Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib vs NVL-655 across ALK activity, mutant activity, CNS activity, and TRK sparing.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:46.16537+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "7bc906df-1b10-4e84-8922-073ff1ff0d0b", "evidence": "Matrix comparing drug generations against clinical outcomes", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:39.871+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "frameworkName": "comparison_table" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 15, "type": "setup", "title": "The slide uses a split-screen layout to contrast in vitro potency (dot plot) with in vivo efficacy (bar chart).", "function": "present_solution", "rawType": "product_demo", "block": null, "metadata": { "slideType": "product_demo", "slideTypeCanon": { "name": "Product demo", "slug": "product_demo", "status": "active", "canonId": "019de52d-0f06-7288-84f2-7568c1020fce", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 51, "componentCount": 5, "textChars": 284, "nDataPoints": 40, "notes": "The slide uses a split-screen layout to contrast in vitro potency (dot plot) with in vivo efficacy (bar chart).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:39.383+00", "seconds": 2.551, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/15", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-15", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.4, "x": 0.55, "y": 0.35 }, "kind": "chart", "text": "In Vivo Activity (Tumor regression)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.383+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5dc095e3-508c-4d39-a9bc-30d3e8cd419d", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.45, "x": 0.05, "y": 0.35 }, "kind": "chart", "text": "In Vitro Activity (IC50)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.383+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6ca4360f-080e-4abe-9e2e-9cc9e942c4f1", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.85 }, "kind": "disclaimer", "text": "BID, twice daily; IC50, half-maximal inhibitory concentration; PO, orally; QD, once daily; V, EML4 breakpoint variant.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.383+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "02c82373-daa8-4332-87d8-41b6c914af6c", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.45, "x": 0.05, "y": 0.63 }, "kind": "list", "text": "Legend for cell lines and mutations", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.383+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff82394d-7f6f-486e-b77e-204d321221bd", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Preclinical Characterization Demonstrates Desired Target Product Profile", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.383+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d8960e1c-9a0a-43af-86f9-d3f98e44a037", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 16, "type": "resolution", "title": "Includes a bar chart for brain penetrance and a dot plot for selectivity index across various mutations.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 51, "componentCount": 5, "textChars": 358, "nDataPoints": 2, "notes": "Includes a bar chart for brain penetrance and a dot plot for selectivity index across various mutations.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:39.823+00", "seconds": 2.952, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/16", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-16", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.2, "x": 0.08, "y": 0.4 }, "kind": "chart", "text": "Unbound brain:plasma ratio for Lorlatinib vs NVL-655", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.823+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "605b2f5e-ce61-4d7f-8ca0-a857d08b9f27", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.2, "x": 0.45, "y": 0.4 }, "kind": "chart", "text": "Selectivity index for ALK over TRKB", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.823+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "63ea9e96-0168-4bda-b496-1e8e64328432", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.85 }, "kind": "source-note", "text": "Head-to-head clinical studies comparing NVL-655 with currently approved or investigational therapies have not been conducted.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.823+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "46b41a55-a756-4b9b-9233-19bd197d5986", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.6, "x": 0.05, "y": 0.18 }, "kind": "title", "text": "Brain-Penetrant with the Potential to Avoid TRK-Related CNS Adverse Events", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.823+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff334da5-0fa8-4ebd-a6c0-dc20f84cd9bf", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Preclinical Characterization Demonstrates Desired Target Product Profile", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:39.823+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "06654c2e-1b99-4fd7-97c8-cddd7fa22f27", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 17, "type": "evidence", "title": "Includes detailed patient enrollment table by dose cohort and trial objectives.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 78, "componentCount": 6, "textChars": 921, "nDataPoints": 42, "notes": "Includes detailed patient enrollment table by dose cohort and trial objectives.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:46.139+00", "seconds": 9.119, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/17", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-17", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.55, "x": 0.39, "y": 0.67 }, "kind": "disclaimer", "text": "1G, 1st generation ALK TKI... Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:46.139+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a6fd528a-e09b-4fa9-b789-56458418001b", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.35, "x": 0.06, "y": 0.35 }, "kind": "list", "text": "PATIENT POPULATION: Advanced solid tumors harboring ALK fusion or activating mutation; Patients with NSCLC: ≥ 1 prior 2G or 3G ALK TKI; ≤ 2 prior chemotherapies/immunotherapies; Excluded: concurrent oncogenic drivers; Evaluable but non-measurable disease allowed", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:46.139+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1852f272-a430-4e23-b26f-5432c555ae76", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.35, "x": 0.06, "y": 0.68 }, "kind": "list", "text": "PHASE 1 OBJECTIVES: Selection of RP2D and, if applicable, MTD (primary); Overall safety and tolerability; PK characterization; Preliminary antitumor activity; Intracranial activity", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:46.139+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b7110f16-8edb-43a1-a5f8-2ed8302e72ba", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.35, "x": 0.06, "y": 0.23 }, "kind": "paragraph", "text": "PHASE 1 DOSE-ESCALATION. Phase 1 enrollment completed February 2024: Updated data to be presented at a medical meeting in 2024", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:46.139+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f081c82a-a1a2-40cb-997a-eb1697ba7025", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.55, "x": 0.39, "y": 0.28 }, "kind": "table", "text": "Enrollment table showing NVL-655 Dose Cohorts (BOIN, Expansion, All-Treated, NSCLC Response-Evaluable) across dose levels (15mg to 200mg QD).", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:46.139+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "52b57cb7-f04e-4a09-b8d4-ba250a8acef6", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.65, "x": 0.27, "y": 0.05 }, "kind": "title", "text": "ALKove-1: A Global First-in-Human Phase 1/2 Clinical Trial of NVL-655 in Advanced ALK-Positive NSCLC and Other Solid Tumors (NCT05384626)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:46.139+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "95b7d852-d90f-4dab-8074-13f5074f44f8", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2e9cef62-0280-4fff-98c0-e39b220e0cd1", "evidence": "table/data: Enrollment table showing NVL-655 Dose Cohorts (BOIN, Expansion, All-Treated, NSCLC Response-Evaluable) across dose levels (15mg to 200mg QD).", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:46.292173+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 17, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "768b9693-f057-40a9-8283-be0c1cfc71ac", "evidence": "The deck presents data on the cost of inaction for cancer patients and how Nuvalent's solution addresses this", "position": 1, "objective": "What is the cost of inaction for cancer patients and how does Nuvalent's solution address this?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:04.726678+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 18, "type": "analysis", "title": "Data cut-off: 8 Aug 2023. Includes detailed breakdown of prior ALK TKI lines and specific mutations.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 51, "componentCount": 3, "textChars": 708, "nDataPoints": 32, "notes": "Data cut-off: 8 Aug 2023. Includes detailed breakdown of prior ALK TKI lines and specific mutations.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:45.056+00", "seconds": 8.013, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/18", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-18", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.45, "x": 0.058, "y": 0.76 }, "kind": "disclaimer", "text": "Data cut-off: 8 Aug 2023. All data shown as n (%) unless otherwise specified. 1G, 1st generation ALK TKI; 2G, 2nd generation ALK TKI; 3G, 3rd generation ALK TKI; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small cell lung cancer; RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1; TKI, tyrosine kinase inhibitor. a Includes patients with untreated CNS lesions. b Cis-allelic configuration not confirmed in all cases. c Categories are not mutually exclusive. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:45.056+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "986465aa-0257-463a-b02a-6fd3ef2a4a54", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.88, "x": 0.058, "y": 0.205 }, "kind": "table", "text": "Patient characteristics and treatment history table for N=93 patients", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:45.056+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f1bd8391-67bc-4b3f-bce3-b002bb37f184", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.55, "x": 0.058, "y": 0.118 }, "kind": "title", "text": "Patient Population: Heavily Pretreated ALK+ Solid Tumors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:45.056+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dc5cd836-32dd-44d2-813b-3b44e06e1bf7", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "5fad3c4b-fdc4-4f8b-bfbe-6b70c0261579", "evidence": "table/data: Patient characteristics and treatment history table for N=93 patients", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:46.355867+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 17, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "768b9693-f057-40a9-8283-be0c1cfc71ac", "evidence": "The deck presents data on the cost of inaction for cancer patients and how Nuvalent's solution addresses this", "position": 1, "objective": "What is the cost of inaction for cancer patients and how does Nuvalent's solution address this?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:04.726678+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 19, "type": "analysis", "title": "Data from ALKOVE-1 Phase 1 trial, presented at AACR-NCI-EORTC 2023.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 3, "textChars": 1168, "nDataPoints": 80, "notes": "Data from ALKOVE-1 Phase 1 trial, presented at AACR-NCI-EORTC 2023.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:40.089+00", "seconds": 3.018, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/19", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-19", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.9, "x": 0.05, "y": 0.78 }, "kind": "disclaimer", "text": "Data cut-off: 8 Aug 2023. Response-evaluable patients with ALK+ NSCLC. 1G, 1st generation ALK TKI (crizotinib); 2G, 2nd generation ALK TKI (alectinib, brigatinib, or ceritinib); CNS, central nervous system; NE, not evaluable; ORR, objective response rate; PD, progressive disease, PR, partial response, RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1; SD, stable disease, TKI, tyrosine kinase inhibitor. a Out of 16 patients harboring presumed compound ALK mutations, 8 have evidence of cis-allelic configuration by central ctDNA analysis. b Includes patients with single G1202R mutation (n=5) and G1202R with compound mutations (n=12; 6 with evidence of cis-allelic configuration). c Includes 4 patients with ongoing partial responses pending confirmation. d Three patients discontinued treatment due to clinical progression without post-baseline radiographic assessment. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.089+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "89054cca-0c4b-4bd2-ba0c-5a93a17df943", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "table", "text": "Table showing ORR and Best Response (PR, SD, PD, NE) across patient cohorts including CNS metastases, resistance mutations, and prior TKI history.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.089+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f5547e0a-f563-4002-ad98-d133f7c8a748", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.9, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Preliminary Activity: Tumor Response Across Heavily Pretreated Patient Populations", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.089+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "40e1403d-c9aa-4309-aed7-14e277cb7c2b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "339702aa-a0e2-4d89-a250-d177a97fa745", "evidence": "table/data: Table showing ORR and Best Response (PR, SD, PD, NE) across patient cohorts including CNS metastases, resistance mutations, and prior TKI history.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:43:46.419248+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 17, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "768b9693-f057-40a9-8283-be0c1cfc71ac", "evidence": "The deck presents data on the cost of inaction for cancer patients and how Nuvalent's solution addresses this", "position": 1, "objective": "What is the cost of inaction for cancer patients and how does Nuvalent's solution address this?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:04.726678+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 20, "type": "evidence", "title": "The slide uses a standard oncology 'swimmer' or 'waterfall' plot format to demonstrate drug efficacy across different patient cohorts.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 465, "nDataPoints": 51, "notes": "The slide uses a standard oncology 'swimmer' or 'waterfall' plot format to demonstrate drug efficacy across different patient cohorts.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:42.963+00", "seconds": 5.868, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/20", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-20", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.8, "x": 0.15, "y": 0.24 }, "kind": "chart", "text": "Waterfall plot of tumor response", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Waterfall chart", "slug": "waterfall", "status": "active", "canonId": "019de52d-002e-733e-b5cf-dd3beb6692cc", "version": 1, "description": null }, "framework": null }, "subkind": "waterfall", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.963+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2a176a0c-7ebf-41b7-aa3a-4d833d7e7ed5", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.83 }, "kind": "disclaimer", "text": "Data cut-off: 8 August 2023. Response-evaluable patients with NSCLC. Four response-evaluable patients not shown due to incomplete or missing post-baseline tumor assessments.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.963+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c50c5f0-697b-4759-ac79-78ac39cdcbeb", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.1, "x": 0.06, "y": 0.3 }, "kind": "legend", "text": "200 mg QD, 150 mg QD, 100 mg QD, 50 mg QD, 25 mg QD, 15 mg QD", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.963+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "124c445f-9bee-4e3b-a14d-bc2ccb807133", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.65 }, "kind": "table", "text": "Dose Level Cohort, Prior ALK TKI, Prior lines chemotherapy, Prior lines anticancer therapy", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.963+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb00847d-6ff9-45c6-a115-22ed9ed46e90", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.65, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Preliminary Activity: Radiographic Tumor Response in Patients With and Without Known ALK Resistance Mutations", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.963+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b0e6e14b-8080-48f6-8ae9-3cacd3b47c05", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "b69ff297-f862-4a30-b1d9-f4869506b2b7", "evidence": "chart/waterfall: Waterfall plot of tumor response", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:43:54.552123+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "053c9790-e0bc-45ea-b6a8-bf07a4c806dd", "evidence": "Standard oncology clinical trial visualization", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:05:42.963+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "waterfall-plot" } ], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 17, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "768b9693-f057-40a9-8283-be0c1cfc71ac", "evidence": "The deck presents data on the cost of inaction for cancer patients and how Nuvalent's solution addresses this", "position": 1, "objective": "What is the cost of inaction for cancer patients and how does Nuvalent's solution address this?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:04.726678+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 21, "type": "evidence", "title": "Swimmer plot showing patient-level treatment duration with ongoing status and response markers.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 5, "textChars": 624, "nDataPoints": 5, "notes": "Swimmer plot showing patient-level treatment duration with ongoing status and response markers.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:40.408+00", "seconds": 3.206, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/21", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-21", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.55, "x": 0.08, "y": 0.18 }, "kind": "chart", "text": "Swimmer plot of treatment duration", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.408+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5daad5b4-c6f3-4df8-a599-f5411c692325", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.25, "x": 0.65, "y": 0.25 }, "kind": "legend", "text": "Legend for prior therapy and patient status markers", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.408+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dcaabc5f-a154-4893-af47-1dd9397cfb68", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.45, "x": 0.47, "y": 0.615 }, "kind": "list", "text": "All patients with RECIST 1.1 tumor response remain on treatment without disease progression; 67% (34/51) response-evaluable patients continue treatment; Median (range) duration of treatment: 3.4 (0.3, 12.3) months; Median (range) time to response: 6.1 (5.1, 12.3) weeks", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.408+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "535965ff-4a0c-49a1-aad8-22a105942014", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.87 }, "kind": "paragraph", "text": "Data as of 8 August 2023, for response-evaluable patients with NSCLC. PD, progressive disease; PR, partial response; QD, once daily; TKI, tyrosine kinase inhibitor. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": "source-note", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.408+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9bdef89d-9143-4b70-ab39-0330fe103dc7", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Time on Treatment: Sustained Duration with Follow-up Ongoing", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.408+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d6634631-9b53-4784-ae5a-ea175c884dda", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 22, "type": "evidence", "title": "Includes two patient case studies with MRI scans showing baseline vs follow-up results.", "function": "show_traction", "rawType": "product_demo", "block": null, "metadata": { "slideType": "product_demo", "slideTypeCanon": { "name": "Product demo", "slug": "product_demo", "status": "active", "canonId": "019de52d-0f06-7288-84f2-7568c1020fce", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 84, "componentCount": 8, "textChars": 807, "nDataPoints": 4, "notes": "Includes two patient case studies with MRI scans showing baseline vs follow-up results.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:41.608+00", "seconds": 4.043, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/22", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-22", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.425, "w": 0.208, "x": 0.727, "y": 0.358 }, "kind": "image", "text": "MRI scans for patient 2", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.608+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "200e2272-2f5e-404f-82c9-d282636a4aa9", "parentComponentId": null }, { "bbox": { "h": 0.425, "w": 0.208, "x": 0.258, "y": 0.358 }, "kind": "image", "text": "MRI scans for patient 1", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.608+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd83b14b-756b-4f98-b837-c30971033aea", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.25, "x": 0.06, "y": 0.335 }, "kind": "list", "text": "EML4-ALK fusion NSCLC with no known ALK resistance mutations; 5 lines of therapy; NVL-655 (50 mg QD); Complete resolution of brain metastases; Treatment continues at 4.2 months", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.608+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6fbcd9a1-bfc7-4997-9ba7-0331796197be", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.25, "x": 0.52, "y": 0.335 }, "kind": "list", "text": "EML4-ALK fusion NSCLC with ALK L1196Q resistance mutation; 3 lines of therapy; NVL-655 (150 mg QD); CNS PR after ~6 weeks; Treatment continues at 3.7 months", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.608+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e05899b2-0760-4bb8-95e4-767ec6b6034f", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.52, "y": 0.275 }, "kind": "paragraph", "text": "Intracranial Partial Response in ALK L1196Q NSCLC:", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.608+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10698898-4c03-4746-a7d0-a9a070c5c1e3", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.06, "y": 0.275 }, "kind": "paragraph", "text": "Intracranial Complete Response in EML4-ALK fusion NSCLC:", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.608+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4cbda1fb-8990-4098-82e3-da3d16e3c79f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.87 }, "kind": "source-note", "text": "Data as of 8 August 2023. CNS, central nervous system; CR, complete response; NSCLC, Non-small cell lung cancer; PR, partial response; QD, once daily; TKI, tyrosine kinase inhibitor. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.608+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d936ba9b-da79-47dd-88eb-6dd2f2747d33", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "CNS Activity: NVL-655 Induced Intracranial Responses in Patients with TKI-Refractory ALK+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.608+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "44d02ea8-f84c-4e00-b28b-4c5e072a05a8", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4ff8c551-4373-4c83-a9c4-92f76919cf76", "evidence": "list/bullet: EML4-ALK fusion NSCLC with no known ALK resistance mutations; 5 lines of therapy; NVL-655 (50 mg QD); Complete resolution of brain metastases; Treatment continues at 4.2 months", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:43:54.672074+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 23, "type": "evidence", "title": "Data cut-off: 8 Aug 2023. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 4, "textChars": 745, "nDataPoints": 32, "notes": "Data cut-off: 8 Aug 2023. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:40.349+00", "seconds": 2.743, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/23", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-23", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.81 }, "kind": "disclaimer", "text": "Data cut-off: 8 Aug 2023. ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; CPK, creatinine phosphokinase; DLT, dose-limiting toxicity; TRAE, treatment-related adverse event. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.349+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fa4f9e37-cf8b-4ee8-a471-6a97fb58741c", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.35, "x": 0.05, "y": 0.25 }, "kind": "list", "text": "MTD has not been identified; 1 DLT: transient asymptomatic Grade 4 CPK increase (200 mg QD). Infrequent TRAEs requiring dose modification: 2 (2%) discontinued, 5 (5%) dose-reduced. Preliminary overall safety profile consistent with avoiding TRK-related neurotoxicities.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.349+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bcaa9b64-c5e6-4848-9c0b-fa7582d19cf7", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.5, "x": 0.425, "y": 0.26 }, "kind": "table", "text": "Treatment-Related Adverse Events (TRAEs) in ≥ 5% of patients. All Treated Patients (N = 93). Columns: Grade 1, Grade 2, Grade ≥3, Any Grade.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.349+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "08da4a16-6af8-4206-ac45-ded78f478185", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Preliminary Safety Profile: Favorable and Consistent with ALK-Selective, TRK-Sparing Design of NVL-655", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.349+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1be3d886-a34b-4648-a3b5-9692c4fc9271", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "93913543-1f8f-4dc3-875e-61475592707d", "evidence": "table/data: Treatment-Related Adverse Events (TRAEs) in ≥ 5% of patients. All Treated Patients (N = 93). Columns: Grade 1, Grade 2, Grade ≥3, Any Grade.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:43:54.752858+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 24, "type": "evidence", "title": "The chart shows pharmacokinetic data across five dose cohorts, demonstrating that the 150mg dose consistently stays above the predicted CNS efficacy thresholds.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 5, "textChars": 513, "nDataPoints": 5, "notes": "The chart shows pharmacokinetic data across five dose cohorts, demonstrating that the 150mg dose consistently stays above the predicted CNS efficacy thresholds.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:40.997+00", "seconds": 3.38, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/24", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-24", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.35, "x": 0.57, "y": 0.3 }, "kind": "chart", "text": "NVL-655 Pharmacokinetics at Steady State (Day 15)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "25755507-96b3-48fa-8728-0432dbea1e38", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.45, "x": 0.05, "y": 0.33 }, "kind": "list", "text": "Maintained steady state plasma levels at or above the target efficacy thresholds; Favorable tolerability; Early anti-tumor activity observed in ALK-positive NSCLC patients.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "75bcc8c3-0091-4dc9-a3ad-c19887f13479", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.05, "y": 0.24 }, "kind": "paragraph", "text": "Selection of 150 mg QD as RP2D was based on the following considerations:", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fed7139f-d432-4195-aec0-b2886f356821", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.4, "x": 0.57, "y": 0.74 }, "kind": "source-note", "text": "Pharmacokinetic data for 200 mg QD cohort are not shown due to immaturity. CNS, central nervous system; QD, once daily. Based on ≥ 100% tumor growth inhibition...", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e5b3bd90-0594-4c49-8ed7-c02948753617", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "RP2D of 150mg QD Met All Desired Clinical Characteristics", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e1653339-b5bb-407e-a9de-98a87a4c18d9", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "7e5f7b10-93f2-4a79-8889-fa33847c6028", "evidence": "chart/line: NVL-655 Pharmacokinetics at Steady State (Day 15)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:43:54.833748+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "8d1e4a8c-f1ea-44b8-8b19-15615718998d", "evidence": "The slide presents clinical evidence (PK data and patient outcomes) to support a strategic decision (RP2D selection).", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:05:40.997+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "frameworkName": "evidence-matrix" } ], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 25, "type": "resolution", "title": "The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and map the drug's value proposition to each.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 83, "componentCount": 7, "textChars": 1085, "nDataPoints": 6, "notes": "The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and map the drug's value proposition to each.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:41.665+00", "seconds": 3.688, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/25", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-25", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.5, "x": 0.05, "y": 0.85 }, "kind": "disclaimer", "text": "Head-to-head clinical studies comparing NVL-655 with currently approved or investigational therapies have not been conducted.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "78ef80a5-2aa1-4b03-a705-1f1e0fb67461", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.65, "y": 0.025 }, "kind": "list", "text": "1L column: Current SOC Alectinib, ALK ~3-5% of NSCLC, ~30-40% CNS disease. Opportunity to supplant SOC with differentiated profile.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2ecd74c2-b0d6-48a5-906c-44b1339d2f29", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.05, "y": 0.025 }, "kind": "list", "text": "3L+ column: No clear SOC, ~25-50% compound mutations, >60% CNS disease. Demonstrated activity in heavily pretreated patients.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a3c1d6c6-47b4-423c-a7b2-677267106758", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.35, "y": 0.025 }, "kind": "list", "text": "2L column: Current SOC Lorlatinib, ~50% single mutations, >60% CNS disease. Opportunity to differentiate with deep, durable responses and TRK-sparing profile.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e18f9dff-def7-48e8-ad79-aa126f597f8a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.88 }, "kind": "source-note", "text": "Sources: Cortellis Sales and Forecasts, accessed November 2023; Ou and Zhu Lung Cancer 2019; Kris et. al. JAMA 2014; Shaw and Engelman J Clin Onc 2013; Noé et. al. J Thor Onc 2019; Peters et. al. NEJM 2017; Shaw et. al. Lancet Onc 2017; Dagogo-Jack et. al. Clin Cancer Res 2019; Lin J.J. et. al., AACR-NCI-EORTC 2023; FDA Package Inserts for alectinib and lorlatinib; Camidge D.R., J Thorac Oncol. 2021.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7f9be80e-0985-42f6-a623-e7df5ab6fa7c", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.7, "x": 0.05, "y": 0.18 }, "kind": "title", "text": "Opportunity to both move up the treatment paradigm & grow the market with deep, durable responses", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5ff7492a-3ace-4548-b33f-32a0479d07cc", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Potential Best-in-class Profile for ALK+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a08d1f5c-88d8-4b0f-bfe9-ee78a77ed75f", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "18b89dae-952a-4272-bfa3-21bd6c4f109f", "evidence": "list/bullet: 2L column: Current SOC Lorlatinib, ~50% single mutations, >60% CNS disease. Opportunity to differentiate with deep, durable responses and TRK-sparing profile.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:43:54.915024+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "9a012132-b9b4-4894-9014-1878d2e492ca", "evidence": "Segmentation by treatment line (1L, 2L, 3L+)", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:05:41.665+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "frameworkName": "market-segmentation-pyramid" } ], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 26, "type": "resolution", "title": "Includes a detailed table of patient cohorts and study objectives.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 5, "textChars": 425, "nDataPoints": 6, "notes": "Includes a detailed table of patient cohorts and study objectives.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:40.748+00", "seconds": 2.672, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/26", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-26", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.3, "x": 0.05, "y": 0.25 }, "kind": "list", "text": "ALKOVE-1 study details and 1L strategy", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.748+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "449d25b9-264d-497c-8157-70ef978d10db", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.87 }, "kind": "source-note", "text": "CBR, clinical benefit rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression free survival; PK, pharmacokinetics; TKI, tyrosine kinase inhibitor; TTR, time to response.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.748+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fff4fcde-6de5-4fd8-9abc-65ef6d5f58c3", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.6, "x": 0.05, "y": 0.18 }, "kind": "subtitle", "text": "Multi-pronged development strategy supports goal of moving up the treatment paradigm", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.748+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7363c82b-3fd1-438a-bc94-2ce527ad60e4", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.55, "x": 0.38, "y": 0.345 }, "kind": "table", "text": "ALKOVE-1 Phase 2 patient cohorts and N values", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.748+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c1c842d-9c9c-4fa8-81c6-cc0692e9e529", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Planned Clinical Development for ALK+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:40.748+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "51572e27-b59f-4da0-ac89-77e43a26c6d6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 27, "type": "resolution", "title": "The slide uses a sidebar 'AT A GLANCE' to summarize key clinical and regulatory status.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 32, "componentCount": 3, "textChars": 431, "nDataPoints": 0, "notes": "The slide uses a sidebar 'AT A GLANCE' to summarize key clinical and regulatory status.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:41.285+00", "seconds": 3.168, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/27", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-27", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 1, "w": 0.29, "x": 0.71, "y": 0 }, "kind": "callout", "text": "AT A GLANCE\nMechanism of Action: ROS1-selective tyrosine kinase inhibitor\nStage of Development: Global Phase 2 with registrational intent\nInitial Development Indication: ROS1-positive NSCLC\nFDA Designations: Orphan Drug Designation", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6eae00f9-2a2d-4e56-8ef1-865e8fc6c5d7", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.55, "x": 0.08, "y": 0.65 }, "kind": "subtitle", "text": "A brain-penetrant, selective inhibitor of ROS1 and ROS1 resistance mutations with the potential to minimize TRK-related CNS adverse events while providing CNS antitumor activity", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6a415b9b-a8d4-4cd6-9eac-a1b472ad88c3", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.08, "y": 0.46 }, "kind": "title", "text": "NVL-520 for ROS1+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.285+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cabd6ef9-4437-4604-a643-6770ae935720", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Call to action", "slug": "call-to-action", "status": "active", "bestFor": null, "canonId": "019dd9e1-4bbb-702a-9ead-82daf188bb7c", "version": 1, "bodyDocId": null, "description": "Explicit prescription of what the audience should do next.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "66e7c45a-40ee-461c-bf5a-0364e84fade5", "evidence": "callout/primary: AT A GLANCE", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:43:55.037857+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 28, "type": "tension", "title": "The slide uses a timeline-based framework to contrast treatment options with clinical limitations.", "function": "frame_problem", "rawType": "customer_journey", "block": null, "metadata": { "slideType": "customer_journey", "slideTypeCanon": { "name": "Customer journey", "slug": "customer_journey", "status": "active", "canonId": "019de52d-0966-70ce-afe3-bc7c98ffc8c9", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 5, "textChars": 190, "nDataPoints": 7, "notes": "The slide uses a timeline-based framework to contrast treatment options with clinical limitations.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:41.397+00", "seconds": 2.879, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/28", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-28", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.65, "x": 0.06, "y": 0.18 }, "kind": "diagram", "text": "1L to 2L+ treatment progression", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.397+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0f944653-e3d3-4fcc-9af7-00d454e15490", "parentComponentId": null }, { "bbox": { "h": 1, "w": 0.25, "x": 0.75, "y": 0 }, "kind": "image", "text": "Illustrative patient image", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.397+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9f2375c8-046d-4910-9f45-5d81dacbcd45", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.7, "x": 0.06, "y": 0.85 }, "kind": "source-note", "text": "Sources: [1] Drilon A. et al... [11] Shaw, A. et al. NEJM 2020.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.397+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bd7e30cf-bd7d-4291-a907-7447ff9f3e5a", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.68, "x": 0.06, "y": 0.32 }, "kind": "table", "text": "Standard of Care and Key Limitations matrix", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.397+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "94ad17c8-11f8-450b-a820-fcec76d47c81", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.11, "y": 0.11 }, "kind": "title", "text": "ROS1+ NSCLC Patient Journey", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.397+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "78b5f064-1841-4024-83bd-4a3d61ee898c", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Customer journey map", "slug": "customer-journey-map", "status": "active", "bestFor": null, "canonId": "019de52d-1b26-7499-98c8-1091acc836be", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "916d957e-90d9-458b-ab62-79fae54724a9", "evidence": "diagram/timeline: 1L to 2L+ treatment progression", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:43:55.118892+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "c71ff29c-0dc6-4188-82dd-f79108e133f1", "evidence": "The slide explicitly maps the patient treatment journey from 1L to 2L+.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:41.397+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "frameworkName": "customer-journey-map" } ], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 29, "type": "setup", "title": "The slide uses a matrix-like structure to compare NVL-520's clinical profile against five competitors (Crizotinib, Entrectinib, Lorlatinib, Repotrectinib, Talet", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 29, "componentCount": 3, "textChars": 362, "nDataPoints": 0, "notes": "The slide uses a matrix-like structure to compare NVL-520's clinical profile against five competitors (Crizotinib, Entrectinib, Lorlatinib, Repotrectinib, Taletrectinib).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:41.603+00", "seconds": 2.725, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/29", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-29", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.65, "x": 0.05, "y": 0.88 }, "kind": "source-note", "text": "Source: Drilon A. et al., EORTC-NCI-AACR 2022. Head-to-head clinical studies comparing NVL-520 with currently approved or investigational therapies have not been conducted.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "94b016fe-f880-421d-b352-1573ca954cf3", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "table", "text": "Comparison matrix of ROS1 inhibitors vs NVL-520 across ROS1 Activity, ROS1 Mutant Activity, CNS Activity, and TRK sparing.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d89537d2-f9b5-4ccc-a493-77ab19272310", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "NVL-520: A Rationally Designed ROS1-selective, TRK-sparing Inhibitor", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:41.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "58b42814-bd93-4309-bed8-333073123247", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "da95ea37-08a5-428f-b10f-f3cb92635426", "evidence": "Comparison table of therapeutic features across multiple competitors.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:05:41.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "frameworkName": "comparison_frame" } ], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 30, "type": "analysis", "title": "Slide presents three distinct preclinical data sets: IC50 viability assays, brain:plasma ratio, and selectivity index vs TRKB.", "function": "analyze_data", "rawType": "product_demo", "block": null, "metadata": { "slideType": "product_demo", "slideTypeCanon": { "name": "Product demo", "slug": "product_demo", "status": "active", "canonId": "019de52d-0f06-7288-84f2-7568c1020fce", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 52, "componentCount": 5, "textChars": 315, "nDataPoints": 25, "notes": "Slide presents three distinct preclinical data sets: IC50 viability assays, brain:plasma ratio, and selectivity index vs TRKB.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:42.21+00", "seconds": 3.257, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/30", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-30", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.35, "x": 0.58, "y": 0.33 }, "kind": "chart", "text": "Avoiding TRK Inhibition", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.21+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c1025622-fe99-471d-8eba-ea89187a5d77", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.15, "x": 0.38, "y": 0.33 }, "kind": "chart", "text": "Brain Penetrance", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.21+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2309e716-3310-4c66-bad2-d07803bc9adb", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.3, "x": 0.05, "y": 0.33 }, "kind": "chart", "text": "In Vitro Activity, ROS1 Wild-type & Mutant", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.21+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f8c30ee6-d36e-48aa-b36e-2ca8623d904d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.85 }, "kind": "disclaimer", "text": "Head-to-head clinical studies comparing NVL-520 with currently approved or investigational therapies have not been conducted. Above data from preclinical studies.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.21+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "75b26006-c195-4d92-8666-5a81865856d6", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Preclinical Characterization Demonstrates Desired Target Product Profile", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.21+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "936be1ca-2a6c-4d5a-9927-be6c8d82772d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 31, "type": "evidence", "title": "The slide presents a summary of a clinical trial, including patient eligibility criteria and a breakdown of patient cohorts by dose level.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 78, "componentCount": 6, "textChars": 1034, "nDataPoints": 25, "notes": "The slide presents a summary of a clinical trial, including patient eligibility criteria and a breakdown of patient cohorts by dose level.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:42.844+00", "seconds": 3.742, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/31", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-31", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.35, "x": 0.06, "y": 0.65 }, "kind": "list", "text": "OBJECTIVES: Selection of RP2D and MTD; Overall safety and tolerability; PK characterization; Preliminary antitumor activity; Intracranial activity", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.844+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0ed2d070-ca75-42e6-b024-99f018676768", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.35, "x": 0.06, "y": 0.35 }, "kind": "list", "text": "PATIENT POPULATION: Advanced solid tumors harboring ROS1 fusions; ≥ 1 prior ROS1 TKI for NSCLC; No limit to prior therapies; Excluded: concurrent oncogenic drivers; Evaluable but non-measurable disease allowed", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.844+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "497e76f1-2f7b-4f8e-aea4-48635ce9fc4f", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.06, "y": 0.22 }, "kind": "paragraph", "text": "PHASE 1 DOSE-ESCALATION. Phase 1 enrollment completed August 2023: Updated data to be presented at a medical meeting in 2024", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.844+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7d3905a0-a5cc-49d4-9bc9-971dbfd56100", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.55, "x": 0.39, "y": 0.75 }, "kind": "source-note", "text": "CNS, central nervous system; DLTs, dose-limiting toxicities; mg, milligram; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; PK, pharmacokinetics; QD, once daily; RP2D, recommended phase 2 dose; ROS1+, ROS1-positive; TKI, tyrosine kinase inhibitor.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.844+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bdaa8e34-61c7-4942-b898-6b35ea2b4395", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.55, "x": 0.39, "y": 0.32 }, "kind": "table", "text": "NVL-520 Dose Cohorts table showing N=35 all-treated population and N=21 NSCLC response-evaluable population across 25mg, 50mg, 75mg, 100mg, 125mg QD doses.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.844+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "360b3e2b-641d-4af6-a1f8-9bac3ec4bdb3", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "ARROS-1: A Global First-in-Human Phase 1/2 Clinical Trial of NVL-520 in Advanced ROS1-Positive NSCLC and Other Solid Tumors (NCT05118789)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.844+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5ebd4d2d-19c1-4e69-8c3b-5890a761d2ea", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 32, "type": "analysis", "title": "Data presented in two tables: Patient Characteristics and Treatment History.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 4, "textChars": 588, "nDataPoints": 30, "notes": "Data presented in two tables: Patient Characteristics and Treatment History.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:44.317+00", "seconds": 5.215, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/32", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-32", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.42, "x": 0.07, "y": 0.8 }, "kind": "disclaimer", "text": "Data as of 13 Sep 2022, for patients treated by 01 Sep 2022. All data shown as n (%) unless otherwise specified. CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small cell lung cancer; RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1; TKI, tyrosine kinase inhibitor. a Includes patients with untreated CNS lesions. b Categories are not mutually exclusive. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:44.317+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "01324122-7ea4-465b-b82f-b5b6fbc4d22d", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.45, "x": 0.48, "y": 0.22 }, "kind": "table", "text": "Treatment History table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:44.317+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4f1c00b1-db3a-420f-b5d2-a912153346a4", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.42, "x": 0.07, "y": 0.22 }, "kind": "table", "text": "Patient Characteristics table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:44.317+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c2cb775a-2b0c-42e1-98e8-f30e6ff13019", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.65, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Patient Population: Heavily Pretreated ROS1+ Solid Tumors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:44.317+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "488859a5-cad3-428b-83a2-ae780883c4fd", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 33, "type": "evidence", "title": "Includes a summary table of ORR and a waterfall plot of tumor regression.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 5, "textChars": 366, "nDataPoints": 45, "notes": "Includes a summary table of ORR and a waterfall plot of tumor regression.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:42.164+00", "seconds": 2.741, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/33", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-33", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.58, "x": 0.38, "y": 0.48 }, "kind": "chart", "text": "Waterfall plot of best percentage change in target lesions.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Waterfall chart", "slug": "waterfall", "status": "active", "canonId": "019de52d-002e-733e-b5cf-dd3beb6692cc", "version": 1, "description": null }, "framework": null }, "subkind": "waterfall", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.164+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d2116445-e3dd-4c47-a064-3b675f7fc98d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.06, "y": 0.23 }, "kind": "list", "text": "NVL-520 induced tumor response across heavily pretreated patient populations. Radiographic tumor regression observed across all NVL-520 dose levels.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.164+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ba4adda5-49d1-4571-9ce5-533d9cd88ef4", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.2, "x": 0.06, "y": 0.89 }, "kind": "source-note", "text": "Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.164+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5f807191-ee25-469b-9d76-4d0d644af7b2", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.58, "x": 0.38, "y": 0.06 }, "kind": "table", "text": "ORR across all dose levels (RECIST 1.1) for various patient cohorts.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.164+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6dff7afd-fe45-42ae-a1e9-37ab59a378e0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.06, "y": 0.06 }, "kind": "title", "text": "NVL-520: ARROS-1 Phase 1 Preliminary Activity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.164+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b124a616-d1cb-4662-a818-332a78382cfb", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "a2e10bb5-8aa6-45f6-a454-531b275b9676", "evidence": "chart/waterfall: Waterfall plot of best percentage change in target lesions.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:43:51.500275+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 34, "type": "evidence", "title": "Includes specific patient subgroup metrics (ORR, tumor shrinkage) and longitudinal imaging.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 88, "componentCount": 8, "textChars": 1103, "nDataPoints": 8, "notes": "Includes specific patient subgroup metrics (ORR, tumor shrinkage) and longitudinal imaging.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:48.073+00", "seconds": 8.207, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/34", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-34", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.15, "x": 0.59, "y": 0.12 }, "kind": "chart", "text": "Reduction in ROS1 G2032R Allele", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:48.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6eab8862-50fb-4cc7-917a-59911ee26a2e", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.2, "x": 0.37, "y": 0.12 }, "kind": "chart", "text": "Reduction in Tumor Burden in Cancers with ROS1 G2032R", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:48.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "47b01e21-d133-4ef1-8279-42efb86f215e", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.18, "x": 0.78, "y": 0.51 }, "kind": "disclaimer", "text": "Data as of 13 Sep 2022, for patients treated by 01 Sep 2022. CNS, central nervous system; ctDNA, circulating tumor deoxyribonucleic acid; NSCLC, non-small cell lung cancer; ORR, objective response rate; PD, progressive disease; PR, partial response; QD, once daily; SD, stable disease; TKI, tyrosine kinase inhibitor.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:48.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0f170143-05fc-40df-8c5d-31e2323faa72", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.25, "x": 0.37, "y": 0.55 }, "kind": "image", "text": "Intracranial Lesions Baseline, 4 weeks, 8 weeks", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:48.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "13e3a3c5-76b1-4c18-9bf8-40e33d5bd82e", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.18, "x": 0.76, "y": 0.12 }, "kind": "legend", "text": "KEY: Each unique color indicates data from the same patient across both figures; PD (due to new lesions and/or progression of nontarget lesions); Prior treatments include repotrectinib.", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:48.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a319ba83-a4b1-40c9-afe6-ab9358ba9d4d", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.3, "x": 0.06, "y": 0.24 }, "kind": "list", "text": "ROS1 Resistance Mutations: Subgroup with known ROS1 G2032R resistance mutation: ORR: 78% (7/9); 100% (9/9) with tumor shrinkage. One patient with ROS1 D2033N with ongoing PR (-40%) pending confirmation.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:48.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10b9be1b-8d00-4933-b151-1702b8ba9f8f", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.3, "x": 0.06, "y": 0.54 }, "kind": "list", "text": "CNS Activity: Intracranial PR in 3/3 patients with measurable (>10 mm) CNS metastases; ORR of 73% (8/11) in response-evaluable patients with history of CNS metastases; No CNS progression observed in any of the 35 treated patients.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:48.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2700a800-7478-47c1-b2fb-b2ce63f16196", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.32, "x": 0.06, "y": 0.06 }, "kind": "title", "text": "NVL-520: ARROS-1 Phase 1 Key Subgroups", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:48.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "22ff6897-31c1-4fd2-95c5-aeb742c8885b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3f1adcf2-c82d-4632-a899-d768a2d4ea01", "evidence": "list/bullet: CNS Activity: Intracranial PR in 3/3 patients with measurable (>10 mm) CNS metastases; ORR of 73% (8/11) in response-evaluable patients with history of CNS metastases; No CNS progression observed in any of t", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:43:51.566074+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 34, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 35, "type": "analysis", "title": "Data as of 13 Sep 2022. Includes list of specific adverse events by grade.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 4, "textChars": 606, "nDataPoints": 24, "notes": "Data as of 13 Sep 2022. Includes list of specific adverse events by grade.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:43.331+00", "seconds": 3.462, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/35", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-35", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.35, "x": 0.05, "y": 0.33 }, "kind": "list", "text": "No DLTs; No treatment-related SAEs; No AEs leading to dose reduction or discontinuation; No treatment-related dizziness", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.331+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "33b45fb1-3a2b-4d54-9506-22d9c93b0d3a", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.6, "x": 0.05, "y": 0.85 }, "kind": "source-note", "text": "Data as of 13 Sep 2022, for patients treated by 01 Sep 2022. AE, adverse event; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; DLT, dose-limiting toxicity; SAE, serious adverse event. a Including oedema and oedema peripheral. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.331+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "df7bbb6d-01ac-4b3a-8e41-c472bea7626d", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.55, "x": 0.38, "y": 0.27 }, "kind": "table", "text": "Treatment-Related Adverse Events (TRAEs) in >1 Patient All Treated Patients (N = 35)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.331+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "571b1da0-dc32-4e11-9791-3cefd5726b45", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "Preliminary Safety Profile: Favorable and Consistent with the Highly ROS1-Selective, TRK-Sparing Design of NVL-520", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.331+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "45da7cd2-3f6e-463e-b47e-b07b3150ad95", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 36, "type": "evidence", "title": "RP2D = Recommended Phase 2 Dose; QD = once daily; MTD = Maximum Tolerated Dose.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 61, "componentCount": 5, "textChars": 571, "nDataPoints": 4, "notes": "RP2D = Recommended Phase 2 Dose; QD = once daily; MTD = Maximum Tolerated Dose.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:42.448+00", "seconds": 2.53, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/36", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-36", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.4, "x": 0.52, "y": 0.27 }, "kind": "chart", "text": "Preliminary pharmacokinetic profile (Presented October 2022)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.448+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c58c756f-8a8d-4b20-9015-187096f8f4e2", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.4, "x": 0.06, "y": 0.4 }, "kind": "list", "text": "MTD was not reached; No clinically significant exposure-response relationships for safety and efficacy were observed; Wide therapeutic window; 100 mg daily maintained steady state plasma levels above all target efficacy thresholds", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.448+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a6309a32-77e5-4758-a0e3-128952b00ade", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.4, "x": 0.06, "y": 0.27 }, "kind": "paragraph", "text": "Favorable tolerability of NVL-520 was observed in 87 ROS1+ patients enrolled across six dose levels (25 mg QD – 150 mg QD) as of May 2023:", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.448+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "61cd91cb-3e76-4b2d-b878-5f5298bee09e", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.06, "y": 0.83 }, "kind": "source-note", "text": "Data as of 13 Sep 2022... Source: Data on file; Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.448+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0706dfad-c795-4e21-b85a-3087e4d21510", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.06, "y": 0.11 }, "kind": "title", "text": "RP2D of 100mg QD Met All Desired Clinical Characteristics", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.448+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9d8abdd4-ad10-4a5f-99b3-79070ed1e752", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 17, "name": "Traction", "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a", "matchId": "1002cb45-bfed-4a82-ae76-5f15589a9979", "beatType": null, "evidence": "The deck presents traction and clinical trial data from slides 17 to 36", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 37, "type": "setup", "title": "The slide uses a comparative structure to contrast the 2L+ (salvage) and 1L (frontline) market opportunities.", "function": "argue_timing", "rawType": "why_now", "block": null, "metadata": { "slideType": "why_now", "slideTypeCanon": { "name": "Why now", "slug": "why_now", "status": "active", "canonId": "019de52d-0f2e-718d-b8ad-256dd87582d0", "version": 1, "description": null }, "function": "argue_timing", "functionCanon": { "name": "Argue timing (why now)", "slug": "argue_timing", "status": "active", "canonId": "019de52d-16f8-74de-9ec2-900be07d90dd", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 90, "componentCount": 9, "textChars": 1080, "nDataPoints": 6, "notes": "The slide uses a comparative structure to contrast the 2L+ (salvage) and 1L (frontline) market opportunities.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:44.092+00", "seconds": 4.119, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/37", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-37", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.3, "x": 0.17, "y": 0.28 }, "kind": "list", "text": "2L+ No clear standard of care (SOC); ~40% ROS1 G2032R mutation; ~30-55% CNS disease", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:44.092+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "22e2c4a6-abdf-4db3-954e-83915966a3e6", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.3, "x": 0.53, "y": 0.28 }, "kind": "list", "text": "1L Current SOC: Crizotinib; ROS1: ~1-3% of NSCLC; ~20-40% CNS disease", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:44.092+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "233cf76e-f83e-44b0-9c98-a01c4d697c27", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.3, "x": 0.53, "y": 0.52 }, "kind": "list", "text": "Potential to address combined medical needs: ROS1 mutation coverage + CNS activity + avoiding off-target adverse events; Opportunity to drive deep, durable responses; Favorable preliminary safety profile", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:44.092+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7e133fe5-aaa6-4de9-82bc-5913ab68086f", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.3, "x": 0.17, "y": 0.52 }, "kind": "list", "text": "Clinical activity observed in heavily pretreated patients with ROS1+ NSCLC: Who likely exhausted all available therapies (ORR: 50%); With ROS1 resistance mutations (ORR: 78%); With history of CNS metastasis (ORR: 73%)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:44.092+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eb4e4dc5-d11a-41be-b396-101366b2c970", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.3, "x": 0.17, "y": 0.44 }, "kind": "paragraph", "text": "Demonstrated activity where current available therapies have failed", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:44.092+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "44fa7a78-cbe4-4587-b0d3-f6a9a3879953", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.3, "x": 0.53, "y": 0.44 }, "kind": "paragraph", "text": "Opportunity to supplant standard of care with a differentiated profile", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:44.092+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "956e9f7e-3984-47b5-83f5-9db528ab0c9f", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.8, "x": 0.058, "y": 0.89 }, "kind": "source-note", "text": "Sources: Cortellis Sales and Forecasts, accessed November 2023; Lin et al., J Thorac Oncol 2017; Gainor et al, JCO Precision Oncol 2017; Ou and Zhu Lung Cancer 2019; Patil et al, JTO 2018; Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:44.092+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f2f9243f-c4ad-4db0-b081-4deb967f6f43", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.75, "x": 0.058, "y": 0.19 }, "kind": "title", "text": "Opportunity to both move up the treatment paradigm & grow the market with deep, durable responses", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:44.092+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c923db50-d5a8-42d2-b744-ad5e6f494d76", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.42, "x": 0.058, "y": 0.118 }, "kind": "title", "text": "Potential Best-in-class Profile for ROS1+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:44.092+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "22a4bcd9-1ca2-4450-af8e-0daa4046cc3b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "1261e3d6-b1ce-454d-994b-9b061ef15ada", "evidence": "list/bullet: Clinical activity observed in heavily pretreated patients with ROS1+ NSCLC: Who likely exhausted all available therapies (ORR: 50%); With ROS1 resistance mutations (ORR: 78%); With history of CNS metastasis", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:43:51.694366+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 37, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 38, "type": "resolution", "title": "The slide outlines a multi-cohort study design with specific patient populations (TKI-naive vs pre-treated) and objectives.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 6, "textChars": 1214, "nDataPoints": 5, "notes": "The slide outlines a multi-cohort study design with specific patient populations (TKI-naive vs pre-treated) and objectives.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:48.734+00", "seconds": 8.741, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/38", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-38", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.3, "x": 0.06, "y": 0.55 }, "kind": "list", "text": "Enrollment planned across North America, Europe, Asia and Australia. All patients receive NVL-520 at 100 mg QD. Primary Objective: ORR by blinded, independent central review. Secondary Objectives: Additional efficacy measures (DOR, TTR, CBR, PFS, OS), intracranial activity, overall safety and tolerability, confirmation of PK profile, PROs", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:48.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4297fdb4-faa7-489a-821f-df787cc81bef", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.06, "y": 0.3 }, "kind": "paragraph", "text": "ARROS-1 for TKI-naïve and TKI pre-treated ROS1+ NSCLC (N ≈ 225). Ongoing global open-label, multi-cohort Phase 2 with registrational intent.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:48.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f89f4282-3110-410d-89a8-db1901756d87", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.58, "x": 0.37, "y": 0.83 }, "kind": "source-note", "text": "1L, 1st line; 2L, 2nd line; CBR, clinical benefit rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression free survival; PK, pharmacokinetics; PRO, patient reported outcomes; QD, once daily; TKI, tyrosine kinase inhibitor; TTR, time to response. a Approximate cohort size, subject to change; b Either crizotinib or entrectinib; c Platinum-based chemotherapy with or without immunotherapy; d With initial TKI of either crizotinib or entrectinib; e Includes NSCLC who do not qualify for any of the other cohorts.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:48.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cd4a5f51-d46a-466f-9c62-5222e7742fc1", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.58, "x": 0.37, "y": 0.27 }, "kind": "table", "text": "ARROS-1 Phase 2: Opportunity for approval in both 2L+ and 1L", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:48.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "16c6596d-22bc-457b-8c2e-527e90771745", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.6, "x": 0.05, "y": 0.18 }, "kind": "title", "text": "Ongoing ARROS-1 Phase 2 supports goal of moving up the treatment paradigm", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:48.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "692f25a0-18b7-42d2-bf5d-1b0aba61dd10", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Clinical Development Strategy for ROS1+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:48.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d4fb9d2-e3f9-4411-a554-76334aaf205b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "df8928dd-5424-486f-a7ad-b52e85923181", "evidence": "Multi-cohort study structure with registrational intent", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:05:48.734+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 38, "frameworkName": "Clinical Trial Design" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 39, "type": "setup", "title": "The slide uses a 'ribbon' or 'banner' layout on the right to highlight key product attributes.", "function": "present_solution", "rawType": "product_demo", "block": null, "metadata": { "slideType": "product_demo", "slideTypeCanon": { "name": "Product demo", "slug": "product_demo", "status": "active", "canonId": "019de52d-0f06-7288-84f2-7568c1020fce", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 5, "textChars": 455, "nDataPoints": 1, "notes": "The slide uses a 'ribbon' or 'banner' layout on the right to highlight key product attributes.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:42.97+00", "seconds": 2.734, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/39", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-39", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.36, "x": 0.6, "y": 0.14 }, "kind": "list", "text": "Mechanism of Action: HER2-selective tyrosine kinase inhibitor. Stage of Development: IND-enabling studies; Phase 1 initiation planned in 2024. Initial Development Indication: HER2-positive NSCLC.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.97+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a91f73fc-624f-4295-a461-936138e09b65", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.36, "x": 0.6, "y": 0.42 }, "kind": "list", "text": "Target Product Profile: Active against HER2 and HER2ex20; EGFR sparing; Brain penetrant.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.97+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a9f47c1e-0dfb-49d9-a819-77ea6071e084", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.53, "x": 0.08, "y": 0.65 }, "kind": "paragraph", "text": "A brain-penetrant, HER2-selective inhibitor with activity against HER2 mutations and the potential to minimize EGFR-related adverse events", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.97+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e9f69533-32de-4ea0-b73d-0ba4b3323393", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.14, "x": 0.715, "y": 0.06 }, "kind": "title", "text": "AT A GLANCE", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.97+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "32ccfbe2-387f-41b9-b93b-52b2978fa7e0", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.42, "x": 0.08, "y": 0.46 }, "kind": "title", "text": "NVL-330 for HER2+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.97+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c9868432-d523-4f39-ab40-4627c8f17fbb", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 40, "type": "resolution", "title": "The slide uses three distinct chart types to demonstrate the drug's efficacy and safety profile.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 51, "componentCount": 5, "textChars": 305, "nDataPoints": 15, "notes": "The slide uses three distinct chart types to demonstrate the drug's efficacy and safety profile.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:47.46+00", "seconds": 7.056, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/40", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-40", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.3, "x": 0.37, "y": 0.2 }, "kind": "chart", "text": "Avoiding EGFR Inhibition", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:47.46+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a1bec5c-005e-4960-9598-bb33af6d49bb", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.25, "x": 0.7, "y": 0.2 }, "kind": "chart", "text": "Brain Penetrance", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:47.46+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c21b8599-191e-4534-b423-1172b9b06c0e", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.3, "x": 0.05, "y": 0.2 }, "kind": "chart", "text": "In Vitro Activity, HER2 AND HER2ex20", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:47.46+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "22fa8a7b-309c-45c4-b2e6-f8d7ecff1bbd", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.87 }, "kind": "paragraph", "text": "No head-to-head clinical studies have been conducted for currently approved or investigational therapies versus NVL-330. Above data from preclinical studies.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:47.46+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c6f7033d-c73c-4aaa-81e6-43f9b3505ffb", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "Preclinical Characterization Demonstrates Desired Target Product Profile", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:47.46+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "381e520b-76c7-4a0b-9a78-5934ce799672", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 41, "type": "resolution", "title": "The slide uses a timeline framework to connect current clinical program statuses to a future milestone.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 38, "componentCount": 4, "textChars": 385, "nDataPoints": 0, "notes": "The slide uses a timeline framework to connect current clinical program statuses to a future milestone.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:43.236+00", "seconds": 2.777, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/41", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-41", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.9, "w": 0.38, "x": 0.615, "y": 0 }, "kind": "callout", "text": "OnTarget 2026: MISSION: Bringing new, best-in-class medicines to patients with cancer", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.236+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a5a55d7e-0d15-451d-9ae7-6eeef98f0dff", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.65, "x": 0.08, "y": 0.16 }, "kind": "framework", "text": "2024: Execute on global registrational strategies; 2025: First pivotal data; 2026: First approved product", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.236+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "603ecb05-e2b1-4744-a4fb-44e1e86c3b4c", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.55, "x": 0.08, "y": 0.42 }, "kind": "list", "text": "Program Status: NVL-520 (ARROS-1 study for ROS1+ NSCLC); NVL-655 (ALKOVE-1 study for ALK+ NSCLC); NVL-330 for HER2+ NSCLC; Additional Discovery Research Programs Ongoing", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.236+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "37b8d165-b33c-4159-b5eb-ee32378bb4a0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.07, "y": 0.08 }, "kind": "title", "text": "The Path to Patient Impact", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:43.236+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "14368d62-15ea-4f42-8389-9cda115331ce", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "f567bd89-5378-4bd2-a6ad-cceedc25eac7", "evidence": "Chronological progression of goals from 2024 to 2026.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:05:43.236+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 41, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 42, "type": "setup", "function": "front_matter", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 5, "componentCount": 2, "textChars": 47, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:05:42.318+00", "seconds": 1.762, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-e431-717d-85d5-60fbb8c86744/42", "deck": "/decks/019de076-e431-717d-85d5-60fbb8c86744", "deckAnchor": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-42", "deckJson": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json" }, "components": [ { "bbox": { "h": 0.28, "w": 0.36, "x": 0.32, "y": 0.36 }, "kind": "image", "text": "Nuvalent logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.318+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "24bda290-ad3f-4359-8faa-e94ebc1d9c7d", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.15, "x": 0.06, "y": 0.81 }, "kind": "paragraph", "text": "www.nuvalent.com\ninfo@nuvalent.com", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:05:42.318+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b34400a9-95cf-4e51-a778-dd35a18b2818", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 9, "to": 9, "label": "Problem", "description": "The deck presents a clear problem statement on slide 9" }, { "from": 10, "to": 10, "label": "Solution", "description": "The deck presents a clear solution on slide 10" }, { "from": 11, "to": 11, "label": "Market Size", "description": "The deck presents market sizing information on slide 11" }, { "from": 17, "to": 36, "label": "Traction", "description": "The deck presents traction and clinical trial data from slides 17 to 36" } ], "loops": [ { "from": 9, "to": 11, "label": "Pattern Hunter", "description": "What are the limitations of current therapies and how does Nuvalent's solution address them?" }, { "from": 17, "to": 20, "label": "Cost Of Inaction", "description": "What is the cost of inaction for cancer patients and how does Nuvalent's solution address this?" } ] }